Increased bone mass in male and female mice following tamoxifen administration

被引:20
作者
Starnes, L. M.
Downey, C. M.
Boyd, S. K.
Jirik, F. R.
机构
[1] Univ Calgary, Alberta Bone & Joint Hlth Inst, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada
[2] Univ Calgary, Schulich Sch Engn, Dept Mech & Mfg Engn, Calgary, AB T2N 4N1, Canada
关键词
tamoxifen; microcomputed tomography (mu CT); trabecular bone; cortical bone; bone mass; Cre recombinase; estrogen receptor; Cre-ER; conditional mutagenesis;
D O I
10.1002/dvg.20294
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tamoxifen is capable of preserving bone mass in gonadectomized rodents as well as intact female mice; however, a detailed 3D quantitative analysis of the structural changes produced in the growing skeleton of intact mice of both genders by this agent is lacking. Employing quantitative microcomputed tomography (mu CT), we assessed the effects of 4-hydroxytamoxifen (OHT) on the femora of C57BL/6J mice administered this agent either for 12 (males and females) or 2 (females) weeks. In mice of either gender, but especially in females, 12 weeks of OHT exposure led to dramatic increases in both cortical and trabecular bone. Females exposed to OHT for either 2 or 12 weeks demonstrated significantly increased cortical wall thickness, trabecular bone volume, connectivity, and number, as well as decreased trabecular separation. Significant increases in several of these parameters were also evident in males after 12 weeks of OHT administration. In view of the expanding use of OHT to induce Cre-mediated recombination events, our findings suggest that care should be exercised when interpreting the skeletal phenotypes of mice exposed this agent, particularly in situations where the effects of OHT might synergize with the phenotypic outcome of a specific genetic alteration.
引用
收藏
页码:229 / 235
页数:7
相关论文
共 43 条
[1]   REGULATION OF INTERLEUKIN-6, OSTEOCLASTOGENESIS, AND BONE MASS BY ANDROGENS THE ROLE OF THE ANDROGEN RECEPTOR [J].
BELLIDO, T ;
JILKA, RL ;
BOYCE, BF ;
GIRASOLE, G ;
BROXMEYER, H ;
DALRYMPLE, SA ;
MURRAY, R ;
MANOLAGAS, SC .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (06) :2886-2895
[2]  
BENZ DJ, 1991, J BONE MINER RES, V6, P531
[3]   Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency [J].
Bilezikian, JP ;
Morishima, A ;
Bell, J ;
Grumbach, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :599-603
[4]  
BORGNA JL, 1981, J BIOL CHEM, V256, P859
[5]   Tamoxifen prevents bone loss in castrated male mice [J].
Broulik, PD .
HORMONE AND METABOLIC RESEARCH, 2000, 32 (05) :181-184
[6]   Effect of testosterone and estradiol in a man with aromatase deficiency [J].
Carani, C ;
Qin, K ;
Simoni, M ;
FaustiniFustini, M ;
Serpente, S ;
Boyd, J ;
Korach, KS ;
Simpson, ER .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (02) :91-95
[7]   Estrogen receptor null mice: What have we learned and where will they lead us? [J].
Couse, JF ;
Korach, KS .
ENDOCRINE REVIEWS, 1999, 20 (03) :358-417
[8]   Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase [J].
Danielian, PS ;
Muccino, D ;
Rowitch, DH ;
Michael, SK ;
McMahon, AP .
CURRENT BIOLOGY, 1998, 8 (24) :1323-1326
[9]   Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal women [J].
Eriksen, EF ;
Langdahl, B ;
Vesterby, A ;
Rungby, J ;
Kassem, M .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (07) :1217-1221
[10]   Ligand-activated site-specific recombination in mice [J].
Feil, R ;
Brocard, J ;
Mascrez, B ;
LeMeur, M ;
Metzger, D ;
Chambon, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) :10887-10890